MA44893A1 - Utilisation de probiotiques dans le traitement et/ou la prévention de la dermatite atopique - Google Patents

Utilisation de probiotiques dans le traitement et/ou la prévention de la dermatite atopique

Info

Publication number
MA44893A1
MA44893A1 MA44893A MA44893A MA44893A1 MA 44893 A1 MA44893 A1 MA 44893A1 MA 44893 A MA44893 A MA 44893A MA 44893 A MA44893 A MA 44893A MA 44893 A1 MA44893 A1 MA 44893A1
Authority
MA
Morocco
Prior art keywords
prevention
treatment
atopic dermatitis
probiotics
lactis
Prior art date
Application number
MA44893A
Other languages
English (en)
Other versions
MA44893B1 (fr
Inventor
López Vicente Manuel Navarro
Boscá Ana Adela Ramírez
Orquín José Manuel Pérez
Vidal Daniel Ramón
Martínez Salvador Genovés
Cuadros María Empar Chenoll
Cortés Francisco Manuel Codoñer
Original Assignee
Bionou Research S L
Korott S L
Biopolis SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56920674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA44893(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bionou Research S L, Korott S L, Biopolis SL filed Critical Bionou Research S L
Publication of MA44893A1 publication Critical patent/MA44893A1/fr
Publication of MA44893B1 publication Critical patent/MA44893B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Confectionery (AREA)
  • Preparation Of Fruits And Vegetables (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Dairy Products (AREA)

Abstract

La présente invention concerne l'utilisation d'une composition probiotique comprenant bifidobacterium animalis subsp. Lactis (b. Lactis), bifidobacterium longum et lactobacillus casei, en particulier les souches b. Lactis cect 8145, b. Longum cect 7347 et/ou l. Casei cect 9104, dans le traitement et/ou la prévention de la dermatite atopique.
MA44893A 2016-07-18 2017-07-18 Utilisation de probiotiques dans le traitement et/ou la prévention de la dermatite atopique MA44893B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382342.0A EP3272396A1 (fr) 2016-07-18 2016-07-18 Utilisation de probiotiques dans le traitement et/ou la prévention de la dermatite atopique
PCT/EP2017/068131 WO2018015388A1 (fr) 2016-07-18 2017-07-18 Utilisation de probiotiques dans le traitement et/ou la prévention de la dermatite atopique

Publications (2)

Publication Number Publication Date
MA44893A1 true MA44893A1 (fr) 2019-05-31
MA44893B1 MA44893B1 (fr) 2021-06-30

Family

ID=56920674

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44893A MA44893B1 (fr) 2016-07-18 2017-07-18 Utilisation de probiotiques dans le traitement et/ou la prévention de la dermatite atopique

Country Status (28)

Country Link
US (2) US12576116B2 (fr)
EP (2) EP3272396A1 (fr)
JP (1) JP6998364B2 (fr)
KR (1) KR102390806B1 (fr)
CN (1) CN110214014B (fr)
AR (1) AR109085A1 (fr)
AU (1) AU2017299137B2 (fr)
CA (1) CA3031002A1 (fr)
DK (1) DK3484585T4 (fr)
EA (1) EA201990086A1 (fr)
ES (1) ES2863398T5 (fr)
HR (1) HRP20210995T4 (fr)
HU (1) HUE055264T2 (fr)
IL (1) IL264282B2 (fr)
MA (1) MA44893B1 (fr)
MX (1) MX2019000821A (fr)
MY (1) MY194858A (fr)
PE (1) PE20190417A1 (fr)
PH (1) PH12019500123B1 (fr)
PL (1) PL3484585T5 (fr)
PT (1) PT3484585T (fr)
RS (1) RS62079B1 (fr)
RU (1) RU2757453C2 (fr)
SA (1) SA519400920B1 (fr)
SI (1) SI3484585T2 (fr)
UA (1) UA126664C2 (fr)
WO (1) WO2018015388A1 (fr)
ZA (1) ZA201900869B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109652349B (zh) * 2019-02-25 2021-03-02 江南大学 一株能够缓解特应性皮炎的长双歧杆菌及其应用
KR102136346B1 (ko) * 2019-12-23 2020-07-22 주식회사 락토메이슨 한국인 영유아 유래 신규한 비피도박테리움 애니멀리스 락티스 lm1017을 유효성분으로 포함하는, 아토피 피부염의 예방 및 치료용 조성물
EP3851115A1 (fr) 2020-01-15 2021-07-21 Biopolis, S.L. Composition probiotique pour son utilisation en tant qu'antioxydant
CN111296842B (zh) * 2020-02-14 2021-01-05 赵一鸣 一种具有抗敏作用的益生菌组合物
CN111528479A (zh) * 2020-05-15 2020-08-14 深圳爱米基因科技有限责任公司 一种缓解特应性皮炎功能的益生菌和益生元组合物及应用
EP3915537A1 (fr) * 2020-05-28 2021-12-01 DuPont Nutrition Biosciences ApS Bifidobactéries pour la prévention, la réduction ou le traitement du vieillissement de la peau
EP3973971B1 (fr) * 2020-09-28 2025-12-31 INSTITUT ALLERGOSAN Holding GmbH Compositions pharmaceutique comprenant un probiotique
CN113430133B (zh) * 2021-06-24 2023-06-23 微康益生菌(苏州)股份有限公司 一种能够缓解溃疡性结肠炎的复合益生菌、制备方法及其应用
KR20240130711A (ko) * 2021-12-16 2024-08-29 바이오폴리스, 에스.엘. 불안 장애의 치료 및/또는 예방에 있어서 포스트바이오틱스의 용도
KR102880991B1 (ko) * 2021-12-17 2025-11-03 박선민 뮤신 분해능을 갖는 혼합 균주 및 그의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004250337A (ja) * 2003-02-18 2004-09-09 Sunstar Inc アレルギー疾患改善用製剤
AU2005291098B2 (en) 2004-10-04 2011-11-24 L'oreal Cosmetic and/or dermatological composition for sensitive skins
CN101165162A (zh) * 2007-09-30 2008-04-23 苏国权 一种益生菌活性制剂
ES2343499B1 (es) * 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
JP5860396B2 (ja) * 2009-05-11 2016-02-16 ネステク ソシエテ アノニム ラクトバチルス・ジョンソニーＬａ１ＮＣＣ５３３（ＣＮＣＭＩ−１２２５）及び免疫障害
EP2251020A1 (fr) * 2009-05-11 2010-11-17 Nestec S.A. Traitement haute température de courte durée qui génère des préparations microbiennes avec des profils anti-inflammatoires
ES2763137T3 (es) * 2009-06-19 2020-05-27 Dupont Nutrition Biosci Aps Bifidobacterias para el tratamiento de diabetes y afecciones relacionadas
EP2228067B1 (fr) * 2010-02-22 2013-12-11 LR Health & Beauty Systems GmbH Composition probiotique et son utilisation
EP2449890A1 (fr) * 2010-11-05 2012-05-09 Nestec S.A. Compositions de céréale en poudre comprenant des micro-organismes probiotiques sans réplication
ES2389547B1 (es) 2010-12-07 2013-08-08 Consejo Superior De Investigaciones Científicas (Csic) Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas.
KR20130049554A (ko) * 2011-11-04 2013-05-14 주식회사 쎌바이오텍 아토피 예방 또는 치료용 조성물
ES2526986B1 (es) * 2013-07-18 2015-11-02 Biopolis, S.L. Nueva cepa de Bifidobacterium animalis subsp. lactis CECT 8145 y su uso para el tratamiento y/o prevención de sobrepeso y obesidad y enfermedades asociadas
CN104605277A (zh) 2013-11-05 2015-05-13 熊涛 一种功能性益生菌发酵果蔬粉的制备方法
KR101545551B1 (ko) * 2013-12-12 2015-08-19 주식회사한국야쿠르트 인슐린 저항성 개선 효능을 갖는 7종의 유산균 복합균주를 유효성분으로 함유하는 조성물
CN103705543A (zh) * 2013-12-25 2014-04-09 广州华农大实验兽药有限公司 一种动物用粪源复方益生菌可溶性粉及其制备方法
KR101724601B1 (ko) * 2014-11-04 2017-04-10 주식회사 쎌바이오텍 아토피 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
CN110214014B (zh) 2024-08-02
US12576116B2 (en) 2026-03-17
PT3484585T (pt) 2021-06-11
MA44893B1 (fr) 2021-06-30
ES2863398T3 (es) 2021-10-11
ES2863398T5 (en) 2026-02-09
PL3484585T3 (pl) 2021-11-22
AU2017299137A1 (en) 2019-02-28
DK3484585T4 (en) 2025-09-08
US20230048705A1 (en) 2023-02-16
KR20190042575A (ko) 2019-04-24
BR112019001116A2 (pt) 2019-04-30
MX2019000821A (es) 2019-12-16
SA519400920B1 (ar) 2024-01-29
PL3484585T5 (pl) 2025-09-22
NZ750450A (en) 2025-07-25
RU2019104462A3 (fr) 2020-08-18
PE20190417A1 (es) 2019-03-19
SI3484585T1 (sl) 2021-08-31
RS62079B1 (sr) 2021-07-30
PH12019500123A1 (en) 2019-04-15
HRP20210995T4 (hr) 2025-11-07
US20190282636A1 (en) 2019-09-19
EA201990086A1 (ru) 2019-12-30
IL264282A (en) 2019-02-28
WO2018015388A1 (fr) 2018-01-25
KR102390806B1 (ko) 2022-04-25
DK3484585T3 (da) 2021-06-21
MY194858A (en) 2022-12-20
IL264282B2 (en) 2024-08-01
SI3484585T2 (sl) 2025-11-28
JP6998364B2 (ja) 2022-01-18
UA126664C2 (uk) 2023-01-11
JP2019521174A (ja) 2019-07-25
EP3484585A1 (fr) 2019-05-22
CA3031002A1 (fr) 2018-01-25
RU2019104462A (ru) 2020-08-18
AU2017299137B2 (en) 2023-03-30
EP3272396A1 (fr) 2018-01-24
CN110214014A (zh) 2019-09-06
EP3484585B2 (fr) 2025-07-09
PH12019500123B1 (en) 2024-02-02
AR109085A1 (es) 2018-10-24
EP3484585B1 (fr) 2021-03-24
HRP20210995T1 (hr) 2021-09-17
HUE055264T2 (hu) 2021-11-29
IL264282B1 (en) 2024-04-01
ZA201900869B (en) 2019-12-18
RU2757453C2 (ru) 2021-10-15

Similar Documents

Publication Publication Date Title
MA43488B1 (fr) Utilisation de probiotiques dans le traitement et/ou la prevention du psoriasis
MA44893B1 (fr) Utilisation de probiotiques dans le traitement et/ou la prévention de la dermatite atopique
NZ777234A (en) Compositions comprising bacterial strains
MX2011012069A (es) Micro-organismos no-replicantes y su efecto inmuno estimulador.
AU2019263623A8 (en) Probiotic Bifidobacterium breve strain and compositions comprising said strain
IT201600091033A1 (it) Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
PH12017502042A1 (en) Dietary supplement
PL2802333T3 (pl) Lactobacillus rhamnosus i Bifidobacterium animalis subsp. lactis do stosowania dla zapobiegania lub leczenia zakażeń górnych dróg oddechowych
PH12018550110B1 (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
EP4253526A4 (fr) Nouvelle souche de bifidobacterium animalis subsp. lactis hem20-01 et composition pour le traitement de la dépression la comprenant ou comprenant une culture de celle-ci
MX383749B (es) Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas
MX2016014991A (es) Composiciones que contienen acido borico y una mezcla de lactobacilos.
AU2024290329A1 (en) Bifidobacterium animalis subsp lactis strain cect 8145 and lta thereof health uses
TR201808116T1 (tr) İnsanlarda ve hayvanlarda kullanilmak üzere yeni̇ probi̇yoti̇k başlatici kültür
PL406051A1 (pl) Zastosowanie kompozycji probiotycznej
PL397178A1 (pl) Kompozycja probiotyczna
CA3297365A1 (fr) Utilisations pour la santé d'une souche bifidobacterium animalis subsp lactis cect 8145 et d'un lta associé
EA201200191A1 (ru) КОНСОРЦИУМ БАКТЕРИАЛЬНЫХ КУЛЬТУР ДЛЯ ПРИГОТОВЛЕНИЯ ЙОГУРТА (Streptococcus thermophiles a1, Lactococcus lactis a1-1, Lactobacillus plantarum sh2, Lactobacillus fermentum pl3, Lactobacillus acidophilus k4, Bifidobacterium longum pl5, Bifidobacterium bifidum ki6)
UA127306U (uk) Комплексний пробіотичний препарат
UA120331U (uk) Пробіотик "болмол"
Lavryk Characteristics of adhesive properties of lactobacillus-clinical isolates and components of biological products
UA89242U (uk) Склад йогурту
RU2012102853A (ru) Штамм lactococcus casei вкпм в-8730, используемый для приготовления кисло-молочных продуктов и пробиотических препаратов
UA105131U (uk) Склад йогурту
LT2013502A (lt) Maistinio arba farmacinio biopreparato kompozicija